What We're Reading: Page 400
Industry reads hand-picked by our editors
Jan 06, 2015
-
-
Economic Times
Japan first nation to approve potential Novartis blockbuster Cosentyx
-
An 18-year record: FDA approved 41 drugs in 2014
-
-
Promising late-stage trial bodes well for Cempra's next-gen antibiotic
-
Massachusetts mulls legal action over marketing practices for pain drugs
-
-
Chiasma raising $56M to develop acromegaly drug—without Roche
-
-
Out with the old: Novartis completes Lilly animal health sale as part of overhaul
Jan 05, 2015
Dec 23, 2014
-
UPDATED: Express Scripts snubs Gilead, will only offer AbbVie's new hep C pill
-
-
-
FDA approves Cubist's novel antibiotic Zerbaxa for complicated infections
-
Actavis considering Almirall acquisition to expand European foothold
-
-
FDA unexpectedly approves AZ's Lynparza for advanced ovarian cancer
-
-
-
CVS Health: Harvoni being prescribed at 2.5 times the rate of Sovaldi
Dec 22, 2014
-
The 14 drugs most likely to top global pharma sales in 2015 and 2020
-
-
Amgen leukemia drug Blincyto's massive price tag: $178,000
-
-
GSK shingles vax shows major promise, could challenge Merck's Zostavax
-
-
Controversial pay-to-delay deals on the decline in the EU
-
-
-
Glaxo assures shareholders: Dividend payout secure despite sluggish sales
Dec 19, 2014
-
-
Actavis reveals post-merger management plans: Saunders to stay as CEO
-
-
Will this Pfizer orphan drug emerge as the Duchenne victor?
-
-
-
14 pharmacy execs arrested, 2 charged with murder over 2012 meningitis deaths
-
Report: Shire still hunting for a deal, maybe with NPS Pharma
-
-
FDA approves Novartis/Alcon's Xtoro for swimmer's ear
Dec 18, 2014
-
The 11 biggest drug launches to watch in 2015
-
-
The US Patent Office just gave a big gift to biopharma companies
-
Historic: FDA approves first-ever system to cut blood transfusion infections
-
Google Ventures ventures more aggressively into healthcare, life sciences
-
Sanofi/Regeneron's opening move on PCSK9 marketing: 'Cholesterol Counts' campaign
-
FDA forces Pfizer to put another warning on antipsychotic Geodon
-
-
-
Former Onyx CEO tackles hard-to-treat CNS diseases with new biotech
Dec 17, 2014
-
-
How Teva's CEO is preparing for a 2015 of patent expirations
-
-
The other victims of scuttled AbbVie-Shire deal? Big banks
-
-
FDA approves two new plasma-based tests, expands use of a third
-
Senate bill would give 15 years' data exclusivity to drugs for unmet needs
-
-
-
Pfizer, OPKO reach growth hormone drug pact worth up to $570M
Previous
